Accessibility Tools

Sunday 15th, December, 2024

11:24 AM EAT

BREAKING NEWS

No data was found

Happening Now!

No data was found
411

Gilead strikes deal to make remdesivir coronavirus treatment in 127 countries

username
This month both the US and Japan authorised remdesivir as a treatment for Covid-19 patients.
WHO on Monday, March 16, 2021 appealed to countries to keep vaccination campaigns going. [PHOTO | FILE]
PHOTO | File

Listen to this article

Enhance your reading experience by listening to this article

The company behind the experimental coronavirus treatment remdesivir has signed non-exclusive licensing deals with five drugmakers based in India and Pakistan to make and sell the antiviral medicine in 127 countries.

Gilead Sciences said the agreements cover almost all of the world’s low-income and lower-middle income countries, including Afghanistan, India, North Korea, Pakistan and South Africa.

The pacts also include several upper-middle and high-income nations.

This month both the US and Japan authorised remdesivir as a treatment for Covid-19 patients.

Many other pharmaceutical companies are racing to develop a Covid-19 drug or vaccine to combat the pandemic.

Before you go…how about joining our vibrant Telegram and WhatsApp channels for hotter stories?

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Viral Stories

APC with turrets at the National Port in Haiti. PHOTO/@MSSMHaiti/X

Haiti gang kills 110 people accused of witchcraft

Former President Uhuru Kenyatta with President William Ruto at his Gatundu home. PHOTO/@4thPresidentKE/X

Ruto visits Uhuru at his Gatundu home

Court gavel. PHOTO/Pexels

Malindi court sentences man to life imprisonment for incest

Nairobi Woman Rep Esther Passaris

‘May this spirit of unity guide us towards a prosperous future’ – Esther Passaris speaks on Ruto’s visit to Uhuru

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

(function(w,q){w[q]=w[q]||[];w[q].push(["_mgc.load"])})(window,"_mgq");

SUBSCRIBE TO OUR NEWSLETTER

Stay informed on the latest news by subscribing to the best categories of your interest.